Literature DB >> 2972626

Ability of monophosphoryl lipid A to augment the antibody response of young mice.

P J Baker1, J R Hiernaux, M B Fauntleroy, P W Stashak, B Prescott, J L Cantrell, J A Rudbach.   

Abstract

Treatment with nontoxic monophosphoryl lipid A increased the magnitude of the immunoglobulin M (IgM) antibody response to type III pneumococcal polysaccharide in young (2- to 4-week-old) mice. This was accompanied by the appearance of significant numbers of IgG1- and IgG3- secreting antibody-forming cells in 4-week-old mice. These findings indicate that monophosphoryl lipid A can be used as an adjuvant to improve the immunogenicity of poorly immunogenic antigens in young, immunologically immature animals.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2972626      PMCID： PMC259701          DOI： 10.1128/iai.56.12.3064-3066.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  25 in total

1.  Pneumococcal antigenic polysaccharide substances from animal tissues.

Authors:  L D FELTON; B PRESCOTT; G KAUFFMANN; B OTTINGER
Journal:  J Immunol       Date:  1955-03       Impact factor: 5.422

2.  Nonionic block polymer surfactants enhance immunogenicity of pneumococcal hexasaccharide-protein vaccines.

Authors:  G J Zigterman; H Snippe; M Jansze; E B Ernste; M J De Reuver; J M Willers
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

3.  Regulation of the antibody response to type III pneumococcal polysaccharide. V. Ontogeny of factors influencing the magnitude of the plaque-forming cell response.

Authors:  H C Morse; B Prescott; S S Cross; P W Stashak; P J Baker
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

Review 4.  Maternal immunization and the immune response of neonates to pneumococcal polysaccharides.

Authors:  C J Lee; Y Takaoka; T Saito
Journal:  Rev Infect Dis       Date:  1987 May-Jun

5.  Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b.

Authors:  D H Smith; G Peter; D L Ingram; A L Harding; P Anderson
Journal:  Pediatrics       Date:  1973-11       Impact factor: 7.124

6.  Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. I. Dose-response studies and the effect of prior immunization on the magnitude of the antibody response.

Authors:  P J Baker; P W Stashak; D F Amsbaugh; B Prescott
Journal:  Immunology       Date:  1971-04       Impact factor: 7.397

7.  Quantitative and qualitative studies on the primary antibody response to pneumococcal polysaccharides at ehe cellular level.

Authors:  P H Baker; P W Stashak
Journal:  J Immunol       Date:  1969-12       Impact factor: 5.422

8.  Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. 3. Studies on the average avidity of the antibody produced by specific plaque-forming cells.

Authors:  P J Baker; B Prescott; P W Stashak; D F Amsbaugh
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

9.  Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine.

Authors:  H Peltola; H Käyhty; M Virtanen; P H Mäkelä
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

10.  Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells.

Authors:  P J Baker; D F Amsbaugh; P W Stashak; G Caldes; B Prescott
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr
View more
  17 in total

Review 1.  Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes.

Authors:  P J Baker
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

2.  Differential sensitivity of CD8+ suppressor and cytotoxic T lymphocyte activity to bacterial monophosphoryl lipid A.

Authors:  F Esquivel; C E Taylor; P J Baker
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

3.  Inactivation of suppressor T cell activity by the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides.

Authors:  P J Baker; C E Taylor; P W Stashak; M B Fauntleroy; K Hasløv; N Qureshi; K Takayama
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

Review 4.  The role of B cells and accessory cells in the neonatal response to TI-2 antigens.

Authors:  Cheri D Landers; R Lakshman Chelvarajan; Subbarao Bondada
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

5.  Adjuvant effects of trehalose dimycolate on the antibody response to type III pneumococcal polysaccharide.

Authors:  P J Baker; M B Fauntleroy; P W Stashak; J R Hiernaux; J L Cantrell; J A Rudbach
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

6.  Immune responses of systemic and mucosal lymphoid organs to Pnu-Imune vaccine as a function of age and the efficacy of monophosphoryl lipid A as an adjuvant.

Authors:  M Garg; B Subbarao
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

Review 7.  The Th1/Th2-like switch in syphilitic infection: is it detrimental?

Authors:  T J Fitzgerald
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

8.  Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A.

Authors:  J E Domer; L G Human; G B Andersen; J A Rudbach; G L Asherson
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3.

Authors:  Dirk J Lefeber; Barry Benaissa-Trouw; Johannes F G Vliegenthart; Johannis P Kamerling; Wouter T M Jansen; Kees Kraaijeveld; Harm Snippe
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 10.  Molecular adjuvants and immunomodulators: new approaches to immunization.

Authors:  A G Johnson
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.